JP2019506392A - がんを処置するための方法 - Google Patents

がんを処置するための方法 Download PDF

Info

Publication number
JP2019506392A
JP2019506392A JP2018537867A JP2018537867A JP2019506392A JP 2019506392 A JP2019506392 A JP 2019506392A JP 2018537867 A JP2018537867 A JP 2018537867A JP 2018537867 A JP2018537867 A JP 2018537867A JP 2019506392 A JP2019506392 A JP 2019506392A
Authority
JP
Japan
Prior art keywords
cancer
compound
formula
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018537867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506392A5 (enExample
Inventor
チャン チア リー，
チャン チア リー，
ローラ ボロジャンスキー，
ローラ ボロジャンスキー，
Original Assignee
ボストン バイオメディカル， インコーポレイテッド
ボストン バイオメディカル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボストン バイオメディカル， インコーポレイテッド, ボストン バイオメディカル， インコーポレイテッド filed Critical ボストン バイオメディカル， インコーポレイテッド
Publication of JP2019506392A publication Critical patent/JP2019506392A/ja
Publication of JP2019506392A5 publication Critical patent/JP2019506392A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018537867A 2016-01-20 2017-01-19 がんを処置するための方法 Pending JP2019506392A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281004P 2016-01-20 2016-01-20
US62/281,004 2016-01-20
PCT/US2017/014163 WO2017132049A1 (en) 2016-01-20 2017-01-19 Methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2019506392A true JP2019506392A (ja) 2019-03-07
JP2019506392A5 JP2019506392A5 (enExample) 2020-02-27

Family

ID=58737850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018537867A Pending JP2019506392A (ja) 2016-01-20 2017-01-19 がんを処置するための方法

Country Status (7)

Country Link
US (2) US20190076392A1 (enExample)
EP (1) EP3405189A1 (enExample)
JP (1) JP2019506392A (enExample)
CN (1) CN109069469A (enExample)
CA (1) CA3011800A1 (enExample)
TW (1) TW201731500A (enExample)
WO (1) WO2017132049A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160949T1 (hr) 2007-09-10 2016-10-07 Boston Biomedical, Inc. Novi sastavi i metode za liječenje karcinoma
WO2014169078A2 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
JP2018511643A (ja) * 2015-04-17 2018-04-26 ボストン バイオメディカル， インコーポレイテッド 癌を治療するための方法
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
US12023335B2 (en) 2018-08-17 2024-07-02 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
CN113164438B (zh) * 2018-10-12 2025-03-18 北京强新生物科技有限公司 治疗化疗难治性癌症的新联合用药方案
WO2025040685A1 (en) * 2023-08-21 2025-02-27 Abliva Ab Quinones for use in the treatment of red blood cell enzymopathies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160949T1 (hr) 2007-09-10 2016-10-07 Boston Biomedical, Inc. Novi sastavi i metode za liječenje karcinoma
KR101714819B1 (ko) 2010-03-19 2017-03-09 보스톤 바이오메디칼, 인크. 암 줄기 세포를 표적화하는 신규 화합물 및 조성물
CA2793527A1 (en) 2010-03-19 2011-09-22 Boston Biomedical, Inc. Use of naphthofuran derivatives in the treatment of cancer
WO2012119265A1 (en) 2011-03-04 2012-09-13 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
WO2014169078A2 (en) * 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
JP2018511643A (ja) * 2015-04-17 2018-04-26 ボストン バイオメディカル， インコーポレイテッド 癌を治療するための方法
CN107847481A (zh) * 2015-06-03 2018-03-27 波士顿生物医药有限公司 包含癌症干性抑制剂的组合物和用于治疗癌症的免疫治疗剂

Also Published As

Publication number Publication date
WO2017132049A1 (en) 2017-08-03
US20190076392A1 (en) 2019-03-14
CN109069469A (zh) 2018-12-21
TW201731500A (zh) 2017-09-16
US20190224157A1 (en) 2019-07-25
CA3011800A1 (en) 2017-08-03
EP3405189A1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
JP2019506392A (ja) がんを処置するための方法
US20180085341A1 (en) Methods for treating cancer
US20190231735A1 (en) Methods for treating cancer
US20180250261A1 (en) Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
US20250235425A1 (en) New Combination Solution for Treating Chemotherapy Refractory Cancer
EP3283070A1 (en) Methods for treating cancer
HK40048413A (en) New combination solution for treating chemotherapy refractory cancer
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии
HK40047114A (en) New combination solution for treating chemotherapy refractory cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210830